LncRNA SNHG6 attenuates ferroptosis in high glucose-treated renal tubular epithelial cells by stabilizing YY1 to activate the PI3K/AKT/GSK-3β pathway
简介:
- 作者: Qiguo Wang, Qin Wang, Xiangyu Meng, Xiaoman Ji, Ting Wang
- 杂志: Archives of Biochemistry and Biophysics
- Doi: https://www.doi.org/10.1016/j.abb.2025.110702
- 出版日期: 2025/12/11
摘要
Ferroptosis has emerged as a critical mechanism contributing to renal tubular epithelial cell injury in diabetic nephropathy (DN), though its mechanisms require further elucidation. This study investigated the expression and regulatory role of long non-coding RNA small nucleolar RNA host gene 6 (SNHG6) in DN-associated ferroptosis. Bioinformatics analysis confirmed the significant downregulation of SNHG6 in DN and its diagnostic value, while real-time quantitative PCR experiments demonstrated that high glucose treatment for 24 h induced the downregulation of SNHG6 in renal tubular epithelial cells HK-2. Overexpression of SNHG6 alleviated high glucose-triggered ferroptosis of HK-2 cells by promoting the expression of glutathione peroxidase 4 and reducing the expression of acyl-CoA synthetase long chain family member 4 and transferrin receptor, manifested by increased cell viability, decreased lactate dehydrogenase activity, and suppressed lipid peroxidation. Mechanistic studies revealed that SNHG6 stabilized YY1 mRNA by promoting its binding to the FUS RNA-binding protein, subsequently activating the PI3K/AKT/GSK-3β signaling pathway to exert a protective effect. Blocking the YY1-PI3K signaling cascade abolished SNHG6 overexpression-mediated inhibition of high glucose-induced cellular ferroptosis. In summary, SNHG6 exerts renoprotective effects in DN by modulating ferroptosis through the YY1-PI3K/AKT/GSK-3β axis.
关于派真
作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。